Immuneering Corp
IMRX$146M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCAMBRIDGE
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Jun 15, 2026
13wMarket Overview
Stock performance and key metrics
IMRX News
Catalyst Timeline
1 upcoming, 1 past
Drug Pipeline
IMM-1-104 Monotherapy (Treatment Group A)
Advanced Solid Tumor
IMM-6-415
Advanced Solid Tumor (Phase 1)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMM-1-104 Monotherapy (Treatment Group A) | Phase 2 | Advanced Solid Tumor | - | - |
IMM-6-415 | Phase 2 | Advanced Solid Tumor (Phase 1) | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply